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Abstract
Background: Directed evolution of biomolecules such as DNA, RNA and proteins containing high diversity has
emerged as an effective method to obtain molecules for various purposes. In the recent past, proteins from non-
immunoglobulins have attracted attention as they mimic antibodies with respect to binding potential and provide
further potential advantages. In this regard, we have attempted to explore a three-finger neurotoxin protein (3F).
3F proteins are small (~7 kDa), structurally well defined, thermally stable and resistant to proteolysis that presents
them as promising candidates for directed evolution.
Results: We have engineered a snake a-neurotoxin that belongs to the 3F family by randomizing the residues in
the loops involved in binding with acetylcholine receptors and employing cDNA display to obtain modulators of
interleukin-6 receptor (IL-6R). Selected candidates were highly specific for IL-6R with dissociation constants and
IC50s in the nanomolar range. Antagonists as well as agonists were identified in an IL-6 dependent cell
proliferation assay. Size minimization yielded peptides of about one-third the molecular mass of the original
proteins, without significant loss of activities and, additionally, lead to the identification of the loops responsible for
function.
Conclusions: This study shows 3F protein is amenable to introduce amino acid changes in the loops that enable
preparation of a high diversity library that can be utilized to obtain ligands against macromolecules. We believe
this is the first report of protein engineering to convert a neurotoxin to receptor ligands other than the parent
receptor, the identification of an agonist from non-immunoglobulin proteins, the construction of peptide mimic of
IL-6, and the successful size reduction of a single-chain protein.
Background
In vitro evolution of proteins is an increasingly promis-
ing approach for introducing desired, novel changes that
can modulate the properties and/or functions of pro-
teins [1]. In this regard, technologies such as phage dis-
play, ribosome display, mRNA/cDNA display and others
[2-6] that couple the phenotype (expressed proteins) to
their genotype (DNA, mRNA or cDNA) have shown
considerable promise, allowing proteins with desired
functions to be selected from large totally random and
scaffold libraries [7].
Protein scaffolds can be either naturally occurring or
de novo synthesized, and have defined structures
that contain amenable regions such as loops that can
be engineered to accommodate completely novel prop-
erties, in particular binding and inhibition [8,9]. Disul-
fide-containing scaffolds, such as a-amylase inhibitor
(tendamistat), bovine pancreatic trypsin inhibitor (BPTI;
Kunitz domain), EETI-II (knottin) and related proteins
are attractive due to their small size, defined structures
and remarkable stability. These scaffolds have been suc-
cessfully engineered for various purposes, such as pro-
tease inhibitors, although none have been reported to
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Here, we report the engineering of a three-finger scaf-
fold that provides a benchmark in the development of
regulatory proteins that can modulate the function of
interleukin 6 receptor (IL-6R).
3F proteins are found in a variety of organisms such
as the elapidae snake and mammals, including humans
[10-13]. These are small proteins (MW: 7-8 kDa) with
4-5 disulfide bonds, b-structure(s) and three protruding
loops that provide the topological basis for the three-
finger structure [10,14]. The striking features of the
3F-protein family are strict conservation of cysteine fra-
meworks and high sequence diversity in the loop (corre-
sponding to finger) regions. This may reasonably make
3F toxins in nature with broad spectrum in target mole-
cules, such as ion channels, receptors, proteases, etc
[14]. This class of protein exhibits high temperature sta-
bility, resistance to proteases and low immunogenicity.
The exceptional specificity of 3F proteins for their
respective receptors, conferred by the residues on the
tips of the loops, has been extensively investigated
[15,16]. These properties make 3F proteins excellent
candidates for evolutionary engineering aimed at obtain-
ing molecules for research, diagnostics and therapeutics.
We chose IL-6R to obtain modulatory molecules from
the 3F snake neurotoxin library. Interleukin-6 (IL-6) is a
multifunctional cytokine regulating cell growth, differen-
tiation, and other cellular functions [17]. The activity of
IL-6 is exerted through IL-6R [17-19], and IL-6 is
known to play a role in the pathogenesis of a variety of
diseases such as Rheumatoid arthritis, Castleman’sd i s -
ease and others [18,20,21]. Therefore, molecules regulat-
ing IL-6R-mediated signaling of IL-6 are important for
research, diagnostics and therapeutics. In this paper, we
report the identification of modulators of IL-6R from a
3F library, and demonstrate the potential of the 3F scaf-
fold in generating novel molecules for macromolecular
receptors. The approach involved the directed evolution
o ft h e3 Fp r o t e i nl i b r a r yu s i n gc D N Ad i s p l a y[ 6 ] .
Further, we identified the functional loops by minimiz-
ing the size of the scaffold while retaining function com-
parable to the intact scaffold. We believe this is the first
report of the engineering of a three-finger scaffold for a
macromolecular receptor, the simultaneous identifica-
tion of agonist and antagonist molecules of IL-6R, the
generation of a peptide mimic of IL-6, and the down-
stream engineering of the scaffold in order to identify
the functional loops.
Results
Overview of cDNA display technology
An overview of the selection process using cDNA dis-
play technology is given in Figure 1A. The puromycin
linker is central to this technology and facilitates rapid
ligation of the mRNA, linking of the expressed protein
to its genotype (mRNA), and rapid reverse transcription
at relatively low temperature (42°C) (Figure 1B). As a
result, unlike related technologies [4,5], the expressed
protein is linked to the cDNA (steps 3-5) which pro-
vides stability to the complex compared to the unstable
mRNA [6]. Furthermore, the stability of cDNA facili-
tates selection under stringent conditions such as pH,
temperature, etc.
Three-finger (3F) library construction and characterization
The 3F scaffold used in this study is a novel snake
a-neurotoxin, MicTx3, isolated from the South Ameri-
can coral snake, Micrurus corallinus. The cysteine
framework of this protein is conserved and is similar to
that of other short a-neurotoxins [10] (Figure 2A).
Biochemical characterization of MicTx3 provided its
affinity (29.5 ± 7.9 nM) for acetylcholine binding pro-
tein (AChBP), and electrophysiological studies of its
inhibition characteristics were determined by the
blockage of nicotinic acetylcholine receptor (nAChR)
a7 currents expressed in Xenopus oocytes (data not
shown). The amino acid residues forming the loops
and b-sheets were deduced by secondary structure
prediction, together with information from the litera-
ture regarding conserved amino acid residues in differ-
ent toxins involved in binding to the nAChR [15,22].
Computer modeling of MicTx3 by superimposition of
its spatial structure (b-sheets and loops) on those of
other neurotoxins was found to be in good agreement
(Figure 2B). The amino acids predicted to form the
loops, including those putatively involved in binding
to acetylcholine receptor, were subjected to randomi-
zation (Figure 2C). Residues T5-P10 in the Loop I
(6 residues), K25-V34 in the loop II (10 residues) and
A46-H52 in the loop III (7 residues) were randomized
and a library constructed (Figure 2A and 2D). The
amino acid residues predicted to form the b-sheets
were left unaltered.
The full construct and sequences adopted for cDNA
display of the 3F protein library are detailed in Addi-
tional file 1, Fig. S1 and Additional file 2, Table S1
online. After transcription, cell-free translation, cDNA
display, purification and quantification, an estimated 1.2
×1 0
11 molecules was obtained and used for the affinity
selection of IL-6R (Figure 1A).
The binding characteristics of the 3F initial library (R0)
were determined by the affinity of the library for immobi-
lized AChBP (a binder of the parental MicTx3) and IL-6R.
It was found that the library binds negligibly to both IL-6R
and AChBP (Figure 3A) suggesting that the library does
n o tb i n dt ot h er e c e p t o r sv i at h ec o n s t a n tr e g i o n s( i.e.,
non-randomized b-sheet residues). These characteristics
ensure that the library is suitable for generating novel
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Figure 1 Overview of cDNA display and construction of the three-finger (3F) scaffold library. (A) cDNA display is based on the formation
of a covalent fusion between the expressed protein (phenotype) and the encoding cDNA (genotype) via a puromycin attached to an
oligonucleotide linker. The puromycin linker is central to this technology (see B). In step 1, the library is prepared with the construct to be
adopted for the cDNA display (Additional file 1, Fig. S1 and Additional file 2, Table S1 online), transcribed into mRNA and ligated to the
puromycin linker in the presence of T4 RNA ligase (steps 2 and 3). The mRNA-linker conjugate is then translated in a cell-free translation system
(reticulocyte lysate) and the covalent linkage between the linker and protein is formed in the presence of high salt (step 4). Rapid purification is
achieved using biotin-streptavidin. cDNA is then synthesized by reverse transcription in step 5 utilizing the ‘built-in’ primer of the linker. In step
6, the genotype-phenotype complex is released from the beads by restriction digestion with PvuII. Further, full length proteins are purified via
the C-terminal 6xHis (step 7). Following selection of molecules against the immobilized targets, the bound molecules are recovered, purified,
amplified (steps 8-10) and used in the next round of selection. (B) Schematic of the Puromycin linker and its functional features. The puromycin
linker used in this study consists of four essential functional features. First, a ligation site for mRNA, a biotin moiety for rapid purification using
immobilized streptavidin (SA), a primer region for reverse transcription and a restriction site for the release of the complex from the immobilized
SA beads.
Naimuddin et al. Molecular Brain 2011, 4:2
http://www.molecularbrain.com/content/4/1/2
Page 3 of 16binding molecules by randomization of the loops, followed
by screening to identify the binding proteins.
In vitro selection of the 3F library
The potential of the 3F library was assessed by searching
the library for novel modulatory molecules of IL-6R.
This was performed by affinity selection of binding
molecules from the initial library over several rounds
during which conditions were progressively made more
stringent (see Methods). After 10 rounds of rigorous
affinity selection, the DNA pools were cloned and
sequenced.
The qualitative binding characteristics of Round 10
library (R10) were analyzed using IL-6R and AChBP
(Figure 3A). The R10 displayed proteins showed negli-
gible affinity for non-coated beads but bound signifi-
cantly to IL-6R, indicating that the R10 library was
enriched in comparison with R0, which did not bind to
IL-6R. No detectable binding was observed to AChBP.
Binding of the 3F-derived proteins is thus specific to
IL-6R. Reduction of the R10 library with DTT resulted
in no binding to any of the proteins tested, indicating
that binding takes place via the protein part of the dis-
played protein (i.e., mRNA-protein) and the protein
loop(s) protruded by forming disulfide bridges between
cysteine residues may contribute to the specific
binding.
Analysis of the sequences revealed that the pool could
be majorly divided into 4 groups based on the similarity
of the loop sequences (Figure 3B). R10-17-like
sequences were 70% of the total clones, followed by
R10-15, R10-13 and R10-14, at 5-10% each. A few muta-
tions were observed in the constant regions, which
could be due to failure of the polymerase proofreading
mechanism as the library underwent totally ~650 cycles
of PCR. Point mutations were also observed in the loop
sequences, indicating that different amino acid residues
may be accommodated in these regions. Silent muta-
tions (different coding sequences expressing the same
amino acid) were also observed at some positions.
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Figure 2 Sequence and structure comparison of MicTx3 with other three-finger proteins. (A) Sequence alignment of MicTx3 and
representative three-finger proteins. Mature forms of MicTx3, erabutoxin A (Ebtx_A; UniProt Acc#P60775), a-cobratoxin (a-Cbtx; P01391), a-
bungarotoxin (a-Bgtx, P60615) and mouse lynx1 (mLynx_1, Q9WVC2) were aligned by Clustal W method using the software, Lasergene ver.7
(DNASTAR, Madison, WI, USA). Conserved cysteine residues among the toxins are highlighted in green, and the disulfide bonds expected from
analysis of a-Bgtx are shown by lines. The number of amino acid residues is shown on the right. (B) Superimposition of three-dimensional
structures of the MicTx3 model and the a-Bgtx experimental structure. The three-dimensional model of MicTx3 was generated by the software,
Internal Coordinate Mechanics (Molsoft, La Jolla, CA, USA), using the a-Bgtx structure (PDBID: 1ik8) as a modeling template. MicTx3 is shown in
red and a-Bgtx is in blue. The numbers in Roman numerals represent the loop numbers. (C) Comparison of the MicTx3 model and the a-Bgtx
experimental structure shown in (B). MicTx3 is shown in red and a-Bgtx is in blue. Disulfide bonds are colored green. In MicTx3, the loop
sections highlighted in fluorescent green show the residues at the tips of the loops that were randomized in order to construct the library. (D)
Schematic of the library based on the 3F scaffold. The anti-parallel b-sheets are depicted as blue arrows and the randomized loop residues are
indicated as red crosses. Numbers such as Y24 and P11 indicate residues adjacent to the randomized residues (also see A). N and C indicate the
amino- and carboxyl-terminals, respectively.
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ment of sequences from the library. C42, which is sup-
posed to form a disulfide bond with C53 in the parent
3F, was found to be mutated to either Y or H in R10-
13, 14 and 15. However, a cysteine residue (C47) was
observed in the loop sequences of R10-14 and 15, which
were subjected to randomization, so there is the possibi-
lity of a disulfide bond between C47 in the third loop
and C53 in the b-sheet of the scaffold. In R10-13, no
cysteine residue was selected either at the 47
th position
or any of the other randomized positions in the third
loop, which could have implications in the folding of
the molecule. The cysteine framework was intact in
R10-17 which was in majority.
Expression of candidate proteins
Recombinant proteins were expressed in Escherichia coli
by two approaches. In the first, the candidates were
fused to the C-terminal of thioredoxin (Trx) and, in
general, more than 50% of the expressed protein was
s o l u b l ef r a c t i o n .I nt h ec a s eo fR 1 0 - 1 4 ,m o r et h a n8 0 %
soluble protein was observed (Figure 4A). In the second,
proteins were expressed without the fusion and were
mostly observed in the insoluble fraction. The insoluble
proteins were recovered as inclusion bodies, purified
and refolded under various conditions (Figure 4B
and 4C). We found that proteins refolded in the pre-
sence of reduced and oxidized glutathione (a redox pair)
had random conformation, as judged from their CD
spectra (Figure 4C (i)). However, when immobilized pro-
tein disulfide isomerase (PDI), a chaperone known to
assist and improve folding/refolding [23], was included
in the redox buffer, we observed spectra resembling b-
sheets (Figure 4C (ii)). Ellipticities near 200 and 215 nm
(spectra in dotted line) indicate a major b-sheet confor-
mation [24]. The fusion and refolded proteins were used
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Figure 3 Binding assay assessment of the quality of the libraries, and the sequences selected. (A) The initial library (R0) and Round 10
library (R10) was prepared by the cDNA display method (up to step 4, Fig. 1A). The R10 library was reduced with dithiothreitol (DTT) to obtain
the R10-D library. All three forms were incubated with non-coated beads, IL-6R coated beads or AChBP coated beads, washed and detected
with Penta.His HRP (see Methods). (B) Sequences of the selected molecules compared to the native 3F sequence (shown as ‘wt’). The loop
sequences that were randomized are shown as letters and the non-randomized b-sheet residues are shown as asterisks. The cysteine residues
are shown in red (C42 and C53 are indicated by arrows). ‘% Population’ indicates the percentage of selected molecules out of the 30 clones that
were sequenced. For example, approximately 70% of the R10-17-like proteins were selected. The sequences were assigned to respective groups
(such as R10-17-like) based on the mutations observed in the loops (shown in italics). Similar loop sequences are shown in the same color.
Mutations in the non-randomized portions are indicated by the mutated residues. C42 and I44 were found to be mutated to Y/H and T residues,
respectively.
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Page 5 of 16for biochemical assays and only the refolded proteins
were used for biological assays.
In vitro biochemical and biological assays
The dissociation constant (Kd) was determined by the
method described by Friguet et al. [25] with a few modi-
fications. The values were found to be in the 48-115 nM
range (Table 1), which are comparable to the dissocia-
tion constants of IL-6 (20 ± 3; Table 1).
The ability of the selected proteins to inhibit the inter-
action of IL-6 with IL-6R was analyzed by an in vitro
biochemical competition assay. We observed that IL-6
inhibited the binding of biotinylated IL-6 to IL-6R with
an IC50 value of 80 ± 3 nM, while the values obtained
for R10-13, R10-14 and R10-15 were 113 ± 7, 164 ± 9
and 102 ± 13 nM, respectively (Table 1). R10-17 was
found to be non-competitive.
The selected proteins, R10-14 and R10-15, were found
to be highly specific to IL-6R, with no apparent affinity
for other proteins such as AChBP and IgG (Figure 5A).
Next, we carried out in vitro biological assays using
the IL-6-dependent DS-1 human B-lymphoma cell line.
A ss h o w ni nF i g u r e5 B ,I L - 6 Rm A bi n h i b i t e dt h eI L - 6
dependent proliferation of cells in a dose dependent
manner (IC50 = 1.2 ± 0.15 nM), and R10-13 was found
to inhibit the growth of cells (IC50 = 1.4 ± 0.3 μM).
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Figure 4 Expression of candidate proteins in Escherichia coli and analysis by circular dichroism. (A) Proteins were expressed as
thioredoxin (Trx) fusions in E. coli. One of the candidates shown here, R10-14, was expressed 80% or more in the soluble fraction at an
expression level of ~100 mg/l. The arrow indicates the R10-14 fusion protein. -Ind denotes uninduced culture, Lys denotes lysate that contains
the total protein after cell lysis, Sol is the soluble fraction after cell lysis and separation of the pellet and Insol is the fraction which contained the
solubilized pellet. (B) Expression of proteins without fusion. Candidates were cloned in pCOLDII vector and expressed in E. coli after cold shock
(4°C) and growth at low temperature (15°C). The expression levels were in the range 10-40 mg/l, and most of the proteins were found in the
insoluble fraction. The insoluble fraction was processed to obtain inclusion bodies and purified on a Ni-NTA affinity column. The expressed and
purified protein is shown as IB, denoting inclusion body, F.T denotes flowthrough, and E1 and E2 are eluates 1 and 2, respectively. R-1 μg
denotes the reference lysozyme used at 1 μg. (C) Circular dichroism spectra of the refolded candidate proteins. Candidate proteins R10-13 and
14 were refolded by two methods. In the first, the reduced proteins were refolded in the presence of reduced and oxidized glutathione by
dialysis as shown in (i) and in the second, the proteins were refolded in the presence of the redox system (glutathione) and immobilized protein
disulfide isomerase (ii). Both spectra are from R10-14.
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no effect on the cell growth. However, we observed that
R10-14 boosted the proliferation of cells and thus specu-
lated that this molecule could be an agonist of IL-6R.
Therefore, we further investigated the potential of R10-
14 to induce cell proliferation in the absence of IL-6
and found that R10-14 indeed induces proliferation even
in the absence of IL-6 and thus acts as an IL-6 mimetic
molecule (Figure 5C, (i) and 5C (ii)). The ED50 (50%
effective dose) values were determined to be 15 ± 2 pM
for IL-6 and 20 ± 6 nM for R10-14 (Figure 5C and
Table 1).
Size optimization of the three-finger scaffold (3F to 1F)
Short peptides retaining the essential features of the 3F
scaffold were generated by size minimization. Peptides
were designed that included the sequences of the scaf-
fold forming the b-sheets, loops and the disulfide bonds
of the selected molecules (see Methods). Thus, the
resulting peptides resemble one of the fingers (1F) of
the three-finger protein (3F)( F i g u r e6 Aa n dA d d i t i o n a l
file 3, Fig. S2 online).
The potency of the designed peptides was assessed
using the biological assay described above. In the case of
R10-14 derived peptides, 13-L2 (which is identical to the
2
nd finger of R10-14; also see Figure 3B) and 14-L3 were
ineffective in inducing cell proliferation. However, 14-L1
(ED50 = 30 ± 5 nM) was as effective as the parent
molecule, R10-14 (ED50 = 20 ± 6 nM), at inducing cell
proliferation. Similarly, in the case of R10-13 derived
peptides, 13-L2 and 13-L3 could not inhibit cell prolif-
eration, however 13-L1 inhibited cell proliferation (IC50
=1 0±1 . 5μM), albeit with a lower potency than the
parent R10-13 (IC50 = 1.4 ± 0.3 μM) (Figure 6B, 6C
and Table 1).
Discussion
Antibodies and its derivatives such as scFv, minibody,
diabody and others have been increasingly used for pro-
tein engineering and directed evolution due to their
high affinity and specificity towards their targets [26].
Recently, however, alternate protein scaffolds that pro-
vide potential advantages over antibodies such as smal-
ler size, easier production and optimization, are showing
promise and are attracting attention [8,9]. Such scaffolds
are comprised of a single polypeptide chain, have
defined structure, and contain amenable regions such as
loops that resemble the complementary determining
regions (CDR) of antibodies. These CDR-like loops can
be utilized to generate large libraries that can be used to
obtain molecules with completely novel properties.
In this regard, we identified and explored a new scaf-
fold, three-finger (3F), for directed evolution and protein
engineering. 3F proteins are small, compact, highly
Table 1 Characteristics of the selected 3F proteins and their derivative peptides
No. Name Sequence
1 aa
2 Disulfide Kd (nM)
3 Function
4 IC50
5 (nM) IC50/EC50
6 (μM)
1 R10-17 SRPRLN GLAPRAIRAQ TPRARTG 70 - 152 ± 10 NC NC -
2 R10-15 QLLACR ATRHTLGHNL ACETPAS 70 - 115 ± 9 C and NI 102 ± 13 NI
3 R10-13 QLLACR ATRHTLGHNL TPRARTG 70 - 48 ± 8 C and I 113 ± 7 1.4 ± 0.3
4 R10-14 APLPYT ATRHTLGHNL ACETPAS 70 - 55 ± 6 C and A 164 ± 9 0.02 ± 0.006
5 13-L1 LVCYQLLASRPGTLETGPDDFTCV 24 C3 and C23 ND I ND 10 ± 1.5
6 13-L2 ETCPDDFTGVATRHTLGHNLTQYCS 25 C3 and C24 ND NI ND NI
7 13-L3 ACAIPTPRARTGC 13 C2 and C13 ND NI ND NI
8 14-L1 LVCYAPLPYTPGTLETGPDDFTCV 24 C3 and C23 ND A ND 0.03 ± 0.005
9 14-L3 IPACETPASC 10 C4 and C10 ND NI ND NI
1Loop sequences of the proteins are for R10-17, 15, 13 and 14. Sequences of individual peptides are shown in full. 13-L1 represents loop 1 of the protein R10-13,
bold letters indicate point mutations, and loop sequences are underlined.
2The number of residues in the proteins (e.g., 70) includes 61 residues of the protein, spacer GGS and 6xHis.
3Affinity was measured by Elisa (25). IL-6 was also assayed and the Kd value was found to be 20 ± 5 nM. ND = not determined.
4NC = Non-Competitive, C = Competitive, NI = Non-Inhibitory, I = Inhibitory, A = Agonist.
5IC50 was determined by ELISA. IL-6 was also assayed and the value was found to be 80 ± 3 nM.
6Measured by IL-6 dependent DS-1 proliferation assay. IC50 = concentration for 50% growth inhibition, which for monoclonal antibody was determined to be 1.2
± 0.15 nM and ED50 = 50% effective concentration, which for IL-6 was found to be 15 ± 2 pM.
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Page 7 of 16specific, stable to thermal and protease exposure, and
are found in a variety of organisms ranging from snakes
to humans [10-13]. Furthermore, molecular evolution
study revealed that the 3F toxin genes show accelerated
evolution, by which the gene product could rapidly
adapt to the environmental changes including prey
species. The evolution rates are significantly higher in
the finger regions. These characteristics make them
excellent candidates for protein engineering and directed
evolution and, thus, potentially useful for research, diag-
nostic and therapeutic uses. We have utilized cDNA dis-
play for the directed evolution of a 3F scaffold library to
obtain molecules that bind to and possibly regulate
interleukin-6 receptor (IL-6R).
cDNA display is based on the formation of a covalent
fusion between the express e dp r o t e i na n dp u r o m y c i n
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Figure 5 Characteristics of the selected candidate proteins. (A) Specificity analysis by competition assay. The candidates (R10-14 and 15
shown here) at 100 nM were incubated with 1 μM IL-6R, AChBP or IgG. The unbound proteins were captured by immobilized IL-6R and
detected using Penta.His HRP. Non-coated beads were used as negative controls and IL-6R beads were used as positive controls (direct binding).
A low signal indicates the specificity of the candidates for IL-6R, while a high signal indicates no apparent affinity for AChBP or IgG. (B)
Assessment of the candidates by biological assay. The candidate proteins were assessed for their potential to inhibit and/or enhance the
proliferation of DS-1 cells (a human B-lymphoma cell line). IL-6R monoclonal antibody was used as a positive control for the inhibition of
proliferation. Graphs are plotted as concentration of IL-6R mAb and peptides vs. % Growth. Open circles denote control (PBS in which IL-6R mAb
and proteins were dissolved), filled diamonds denote IL-6R mAb (purple line), filled squares denote R10-13, inverted filled triangles denote
R10-14, filled circles denote R10-15 (black line) and open triangles denote R10-17. (C) Assessment of the agonist activity of R10-14. The candidate
protein, R10-14, which enhanced the proliferation of cells in (B), was assessed for its potential to enhance cell proliferation in the absence of IL-6;
(i) shows the dose-dependent proliferation of cells by IL-6 and (ii) shows the dose-dependent proliferation of cells by R10-14. Proper controls
such as PBS were included. ED50 for IL-6 and R10-14 were determined to be 15 ± 2 pM and 20 ± 6 nM, respectively.
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Figure 6 Biological assessment of the size-optimized peptides from the selected candidate proteins. (A) The size optimization strategy
was designed to obtain peptides resembling three single fingers between 12-25 residues long (see Additional file 3 Fig. S2) from the parent
candidate proteins which are 61 residues long (i). The spatial structures of the parent protein (i) and the derived peptide containing Loop I (ii)
are given (disulfide bonds are shown in green and the fluorescent green denotes different loop sequences. (B) Assessment of the peptides as
agonists of IL-6R. R10-14 (i) and the designed and chemically synthesized peptides 14-L1 (ii) were assessed for their ability to stimulate the
proliferation of DS-1 cells in the absence of IL-6 in a dose-dependent manner. (C) Assessment of the peptides as antagonists. R10-13 (i) and the
designed and chemically synthesized peptides 13-L1 (ii) were challenged in the IL-6 dependent proliferation of DS-1 cells in a dose-dependent
manner.
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Page 9 of 16linked to the genotype (cDNA). Briefly, a DNA linker
containing puromycin is rapidly ligated to the mRNA.
Following protein expression, puromycin forms a cova-
lent fusion with the protein on the stalled ribosome
[4,5]. This is followed by rapid purification of the com-
plex, facilitated by the biotin-streptavidin pair, and sub-
sequent cDNA synthesis utilizing the ‘built-in’ primer
contained in the linker. Thus, the protein, which is
covalently attached to the puromycin-linker, eventually
gets linked to the cDNA (Figure 1A) [6]. This process is
extremely fast, prevents degradation of the mRNA por-
tion and thus contributes to prepare the library intact in
quality and size, which are crucial for the subsequent
selection of molecules. The cDNA display technology
utilizes a cell-free translation system and, as a result, is
capable of generating libraries in the order of 10
12-14,
compared to 10
8 in the case of cell-dependent methods
such as phage display [3].
Affinity selection of the 3F library aimed at identifying
novel molecules binding to IL-6R enriched the library
with proteins specific for IL-6R; the sequences of these
proteins were divided into different major and minor
groups (Figure 3). The selected candidates bound to IL-
6R with affinity (nanomolar range) and specificity simi-
lar to that of antibodies in the biochemical assays. Can-
didates that competed with the natural ligand, IL-6,
were also successfully obtained. Antagonists as well as
agonists were identified biologically using an IL-6
dependent cell proliferation assay (Table 1). These
results demonstrate the potentials of the 3F scaffold to
accommodate residues, different from the parent resi-
dues, which are required to generate high-diversity
libraries and then to utilize the libraries for obtaining
novel ligands for macromolecular targets such as IL-6R
by iterative selection. Disulfide-rich proteins such as
knottin, tendamistat and others have been shown to be
useful as templates to search for protease inhibitiors,
however, none have been shown to bind and/or regulate
the activity of macromolecular receptors [8]. Our results
show for the first time that regulatory molecules against
receptors can be obtained by the directed evolution of
the 3F scaffold.
The 3F scaffold provides potential advantages over
related scaffold proteins that have been successfully used
for directed evolution. 3F (~6.7 kDa) is smaller than
many other proteins such as scFv (~30 kDa), DARPin
(~20 kDa), lipocalin (~20 kDa), fibronectin (~10 kDa)
and zinc-finger (~9 kDa), and is comparable to Affibody
(~6 kDa); these proteins have been used for the purpose
of directed evolution [9]. The number of residues in the
loops that can be utilized for the construction of libraries
is around 38%, which is larger than that of published
scaffolds such as ~10% (scFv) [26], ~22% (Affibody) [27],
~22% (fibronectin) [28], ~26% (zinc-finger) [29], ~9%
(lipocalin) [30], ~21% (DARPin) [31], and others. The
greater flexibility regarding the residues that can be ran-
domized provides a larger interaction surface between
the binding partners during the binding event. The dis-
covery of an agonist in the 3F library also demonstrates
the utility of this approach, particularly from the view-
point that agonists have been identified from immuno-
globulin sources [32-34] and random peptide libraries
[35,36], but there are no published reports of agonistic
molecules from non-immunoglobulin proteins [9]. The
high affinity and remarkable specificity of 3F proteins for
their targets, along with their stability, make this scaffold
suitable for diagnostic, therapeutic and protein chip pur-
poses. Furthermore, the presence of a single lysine (K58)
near the C-terminus in the 3F molecule used in this
study will facilitate homogeneous labeling of the 3F pro-
t e i n sw i t hc h e m i c a lm o i e t i e ss u c ha sf l u o r e s c e i n ,b i o t i n
and other labels and probes that can be exploited for
research and diagnostic purposes (e.g., fluorescence ima-
ging of tumors, protein chips, ELISA).
When the candidate proteins were expressed in E. coli
as recombinant proteins in fusion with thioredoxin, more
than 50% of the expressed proteins were found in the
soluble fraction; one of the candidates, R10-14, showed
more than 80% soluble protein (Figure 4A). Similarly, the
candidates also expressed well at 1-2 mg/ml of cell-free
lysate when produced as maltose binding protein fusions
in a bacterial cell-free translation system such as RTS
(Roche, Penzberg, Germany), with nearly all of the pro-
tein present in the soluble fraction and checked for their
binding activities for IL-6R (data not shown). In contrast,
disulfide-rich proteins are known to be poorly expressed
in the native form in bacteria, and generally tend to form
i n c l u s i o nb o d i e s[ 3 7 ] .I na na t t e m p tt op r o d u c en o n -
fusion proteins in bacteria, we observed that the proteins
aggregated as inclusion bodies (Figure 4B). However, by
using a refolding system that included the redox buffer
and immobilized protein disulfide isomerase, the proteins
seem to be refolded from the analysis of circular dichro-
ism (Figure 4C). Further, 3F proteins can also be success-
fully produced in the native state using Pichia pastoris as
the host system [38].
The 3F proteins are leaf-like, flat molecules with the
three fingers extending from a globular head [39,40].
Taking advantage of this structure, we designed a strat-
egy to minimize the size of selected 3F proteins into
three, single finger peptides, which lead to three inter-
esting results. First, the size was successfully reduced to
24 residues compared to 61 residues in the parent 3F,
and thus can be conveniently prepared by chemically
synthesis and facilitate molecular dynamic studies; sec-
ond, we identified the effector fingers which retained
activity; third, function was observed in the 1
st finger, i.
e., 13-L1 and 14-L1 (Table 1).
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DARPins and avimers have been successfully moderated
in size (reduced or increased) due to the modular nature
of parent proteins [31,41], however, there are no reports
of other single-chain proteins, such as fibronectin, lipo-
calins and affibodies, being successfully reduced in size.
The possibility of further size reduction of monomers in
DARPins (the monomer consists of 33 residues) and avi-
mers (a monomer containing 35 residues) has also not
been investigated. Therefore, we believe that this is the
first report of the successful reduction of a single-chain
3F scaffold to shorter peptides of only 24 residues which
retain activity comparable to that of the parent protein.
Recently, ~3 kDa peptides derived by rational design
from VH (complementarity region) and VL (framework
region) domains of Fab have been shown to mimic the
parent antibody [42]. Encouraged by these results, the
concept of single finger libraries will be interesting to
pursue and might be more attractive.
IL-6 is a pleiotropic cytokine involved in the regula-
tion of cell growth, differentiation and various other cel-
lular functions [17], and is known to play a role in the
pathogenesis of a variety of diseases [18,20,43-46] and in
brain injury [47,48]. Therefore, both antagonist and ago-
nist molecules that can regulate the IL-6R-mediated sig-
naling of IL-6 are important for research, diagnostic and
therapeutic purposes. An antibody that acts as an
antagonist of IL-6R has been reported [49]; however,
there are no reports of agonists of IL-6R. The present
study generated R10-13, which has a size 1/20
th that of
an antibody and an IC50 of 9.8 μg/ml (IC50 = 0.18 μg/
ml of mAb, as determined in this study), and also 13-
L1, which has a size 1/57
th that of an antibody, and an
IC50 = 26 μg/ml. In different reports, IC50 values for
peptides selected by phage display and rational design
were reported in the range 25-60 μg/ml [50,51]. 3F
derived peptides are, therefore, potentially capable of
inhibiting the IL-6R-mediated signaling. R10-14 (ED50
= 140 ng/ml) and 14-L1 (ED50 = 79 ng/ml) can poten-
tially be developed and used as agonists of IL-6R (ED50
= 0.5 ng/ml of IL-6 as determined by this assay) either
to supplement IL-6, or used when IL-6 is deficient.
It is noteworthy that the directed evolution of 3F
library which was carried out using the soluble extracel-
lular IL-6R generated molecules having comparable affi-
nity and competitive potential to IL-6 (Table 1).
However, in cellular assays the peptides were found to
be less potent either as antagonist or agonist compared
to IL-6R mAb and IL-6 showing approximately
100 times lesser activity. The antagonist and agonist
molecules developed in this study, however, have com-
parable or better efficacy than those previously reported.
Martin et al. obtained a clone from affibody library with
an affinity in the micromolar range and antagonist func-
tion [52], Su et al. [50] and Feng et al. [51] reported
peptides with IC50 in the range 25-60 μg/ml. Further,
phage display based selections of constrained cyclic
libraries have been reported to generate agonists in the
micromolar range [35,36]. The above peptides and pro-
teins obtained in this study may be regarded as lead
molecules from the viewpoint of potency, which can be
increased further by exploiting affinity maturation of the
parent 3F candidates [53,54] optimization by dimeriza-
tion or multimerization of the peptides [55-57], and
other approaches. These lead molecules were generated
by directed evolution of a 3F protein library. Therefore,
3F library used in this study provides a platform to
obtain regulatory molecules of IL-6 receptor and, in
principle, other macromolecules.
In analogy to 3F scaffold, other peptide scaffolds origi-
nating from accelerated evolution such as inhibitor
cysteine knot may also be utilized as templates for ran-
dom peptide libraries.
Conclusions
We have constructed a high diversity library utilizing
3F scaffold as a template and randomizing the loops
with which the parent molecule binds to its natural
receptor. This library was screened against soluble
extracellular IL-6R and yielded ligand molecules that
bind with high affinity to the receptor comparable to
IL-6. These ligands have both antagonist and agonist
function as revealed in a cellular assay. We have also
successfully achieved size reduction of this single chain
scaffold into single fingers without significant loss of
activity. Therefore, 3F proteins are promising candi-
dates for protein engineering, and directed evolution
can be used to generate molecules for research, diag-
nostic and therapeutic uses.
Methods
Preparation of the three-finger library
A full construct for preparing the three-finger (3F) pro-
tein library was designed to facilitate the formation and
purification of cDNA displayed proteins. The 3F genetic
construct was prepared by joining the fragments by over-
lap PCR (see Additional file 2, Table S1 and Additional
file 1, Fig. S1 online). Briefly, to the sequence of the 3F
library, SP6 fragment containing the SP6 promoter, cap
site, Xenopus globin untranslated sequence (UTR) and
translation initiation site was added at the 5’ end, while
the (G3-S)2 spacer, C-terminal 6xHis, (G3-S) spacer and
Y-tag sequences were added at the 3’ end (Additional file
1, Fig. S1). The final library was expressed and purified
by Ni-NTA agarose (Qiagen, Valencia, CA, USA) and the
library’s quality was assessed by sequencing 20 clones
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Page 11 of 16picked at random after cloning them into the TA cloning
vector (Invitrogen, Carlsbad, CA, USA).
Transcription of library DNAs
The above library DNAs were subjected to polyacryla-
mide gel electrophoresis (PAGE), purified from the gel,
and then annealed by heating at 94°C and gradient
cooling to form the correctly paired double-stranded
DNA. The template DNAs were transcribed by SP6
RNA polymerase in a RiboMAX Large Scale Produc-
tion Systems (Promega, Madison, WI, USA). Reactions
were terminated by adding DNase I and products were
purified using the phenol/chloroform method. RNA
concentration was measured by a spectrophotometer at
260 nm.
Synthesis of the puromycin-linker
The puromycin-linker was synthesized, as described
previously [6], by cross-linking two modified oligonu-
cleotides with the hetero-bifunctional reagent, EMCS
(N-(6-maleimidocaproyloxy) succinimide) (Figure 1B).
The modified oligonucleotides, Puro-F-S [5’-(S)-TC
(F)-(Spec18)-(Spec18)-(Spec18)-(Spec18)-CC-(Puro)-3’]
and Biotin-loop [5’-CCCGGTGCAGCTGTTTCATC
(T-B) CGGAAACAGCTGCACCCCCCGCCGCCCCCCG
(T)CCT-3’] were custom synthesized (BEX Co., Tokyo,
Japan). The symbol (S) denotes 5’-thiol-modifier C6, (F),
fluorescein-dT; (Puro), puromycin CPG; (Spec18), spacer
phosphoramidite 18; (T), amino-modifier C6 dT; (T-B),
biotin-dT. The underlined sequence indicates the cutting
site of restriction enzyme PvuII) All phosphoramidite
reagents used for modifications were from Glen Research
(Sterling, VA, USA).
Ligation of mRNA to the linker
mRNA was annealed to the biotinylated puromycin-
linker DNA (1:1 ratio) via the Y-tag sequence in 1×
ligase buffer (Takara, Kyoto, Japan) by heating at 94°C
and cooling slowly. mRNA and linker were ligated by
the addition of T4 kinase (3 U) and T4 RNA ligase (20
U) (Takara) at 25°C for 1 h, then the conjugated pro-
duct was purified using an RNeasy Kit (Qiagen). Liga-
tion efficiency and the purity of the products were
checked by polyacrylamide gel electrophoresis using
FITC and/or VistraGreen (Molecular Probes, USA)
staining on a fluoroimager (Bio-Rad, Hercules, CA,
USA).
cDNA display
mRNA-puromycin linker DNA (3-5 picomoles) was
translated in 25 μl using a Rectic Lysate IVT Kit
(Ambion, Austin, TX, USA) at 30°C for 10 min. After
translation, proteins were covalently linked to the pur-
omycin linker in the presence of 65 mM MgCl2 and
750 mM KCl at 37°C for 2 h. Purification was achieved
using the biotin-streptavidin interaction for 10-15
m i n . ,f o l l o w e db yM - M L Vr e v e r s et r a n s c r i p t a s e
(Takara) reaction to form the cDNA/mRNA hybrid
utilizing the ‘built-in’ primer included in the linker
(Figure 1B). Displayed proteins were released from the
biotin-streptavidin complex upon digestion with 12 U
of PvuII restriction enzyme in the supplied buffer at
37°C for 1 h. Full length displayed proteins were puri-
fied utilizing the C-terminal 6xHis-tag by Ni-NTA
magnetic beads (Qiagen). The purified display proteins
were quantified by fluorescence using a Beacon 2000
(Panvera, WI, USA) and a known FITC-labeled DNA
as standard.
The whole process was scaled up for library prepara-
tion where 200 pmols was used for translation; the sub-
sequent rounds were reduced to 1/5
th for R2-R5 and 1/
10
th for R6-R10.
Library quality assessment
The affinity of the initial 3F library (R0) was checked by
a binding assay for immobilized IL-6R and AChBP (see
immobilization procedures in the next section). Equal
amounts of 3F library prepared by cDNA display (up to
step 4, Figure 1A) were incubated with non-coated
beads, 250 nM IL-6R or AChBP coated beads for 1 h at
room temperature in PBS. Each mixture was washed
with PBS-T (0.1% Tween) and subsequently incubated
with Penta.His-HRP (Qiagen) in PBS-T for 30 min. at
25°C. The mixtures were washed several times with
PBS-T followed by the addition of substrate, 3, 3’,5 ,5 ’-
Tetramethylbenzidine (TMB; Sigma, Saint Louis, USA).
After color development was complete, the reaction was
stopped by the addition of 0.5 M H2SO4, each mixture
was centrifuged, and absorbance was measured at 450
nm.
Preparation of immobilized proteins
Extracellular IL-6R (PeproTech, London, UK), AChBP
(cDNA was cloned from Aplysia kurodai [manuscript in
preparation] and the recombinant protein was expressed
in E. coli and purified in our laboratory), IgG (human
immunoglobulin; Sigma) and BSA (Ambion) were
immobilized on NHS-activated Sepharose 4 Fast Flow
(Amersham Biosciences) utilizing the amine coupling
chemistries to form a chemically stable amide bond
according to manufacturer’s instructions. Coupling effi-
ciency was estimated by absorbance measurements of
initial and unbound protein at 280 nm. The activity of
the immobilized proteins (except for BSA) was mea-
sured by ELISA using either biotinylated or 6xHis con-
taining ligands. Non-coated beads were also prepared by
the same derivatization procedure, but in the absence of
protein.
Naimuddin et al. Molecular Brain 2011, 4:2
http://www.molecularbrain.com/content/4/1/2
Page 12 of 16Selection of IL-6R binders
The above 3F library was screened to identify mole-
cules selectively binding to IL-6R. Each round of selec-
tion was performed with the non-coated beads and IL-
6R coated beads in a batch-selection mode using Phos-
phate Buffered Saline (PBS) containing an additional
100 mM NaCl and 0.1% Tween-20. The initial round
contained 2 nM cDNA displayed protein and 300 nM
IL-6R. Prior to the selection of IL-6R binders, non-spe-
cific Sepharose binders were excluded by preincubation
of the library with non-coated beads for 1 h. This was
followed by incubation of this precleared library with
IL-6R coated beads for 1 h. After incubation, the IL-6R
beads were washed several times with the PBS/NaCl/
Tween-20 buffer and eluted with the same buffer con-
taining 100 mM DTT (dithiothreitol, Sigma). The
eluted products were desalted and PCR amplified (con-
ditions described above) with PCR forward and reverse
primers (see Additional file 2, Table S1 online), puri-
fied and used as templates for PCR amplification with
the SP6 fragment. The DNAs were gel purified, tran-
scribed, mRNA ligated to puromycin linker, translated,
transformed into display proteins, reverse transcribed,
Ni-NTA affinity purified, quantified and used for the
next round of selection. The concentration of IL-6R
and the incubation time were gradually reduced from
300 nM to 30 nM and from 1 h to 15 min, respec-
tively, while the number of washes increased progres-
sively during further rounds of selection in order to
apply selection pressure. In round 9 and 10, 30 nM
biotinylated IL-6R was used.
After 10 rounds of stringent selection the eluted pool
was PCR amplified, cloned into TA cloning vector (Invi-
trogen) and sequenced.
Assessment of the selection
Direct binding analysis using displayed proteins:
Selected Round 10 library (R10) was prepared by the
cDNA display method (up to step 4 of Figure 1A) and
purified by spin columns (Bio-Rad). One of the fractions
was denatured by treatment with 100 mM dithiothreitol
(DTT) for 1 h and purified (designated as R10-D).
Purified display proteins (R10 and R10-D; 5 μl) were
mixed with non-coated beads and 250 nM of IL-6R or
AChBP coated beads in PBS-BSA (0.01% BSA) and incu-
bated at 25°C for 1 h. The mixtures were washed with
PBS-T (0.1% Tween) and subsequently incubated with
Penta.His-HRP (Qiagen) in PBS-T for 30 min. at 25°C.
The mixtures were then washed several times with PBS-
T followed by addition of the substrate, 3, 3’,5 ,5 ’-tetra-
methylbenzidine (TMB; Sigma). After color development
was complete, the reaction was stopped by the addition
of H2SO4, the sample was centrifuged, and absorbance
measured at 450 nm.
Protein preparation
Proteins were prepared as thioredoxin fusions using the
pBAD/TOPO Thiofusion expression Kit (Invitrogen).
Thioredoxin (Trx) was also prepared for control experi-
ments. The selected candidates were PCR amplified
(encoding C-terminal 6xHis), cloned into pBAD/TOPO
Thiofusion expression vector and transformed according
to the manufacturer’s instructions. Frames were ana-
lyzed by sequencing.
T h ep o s i t i v ec l o n e sw e r ec u l t u r e di nL u r i a - B e r t a n i
(LB) medium containing 50 μg/ml ampicillin at 37°C
for 16 h. A small portion of the culture was transferred
t of r e s hL B - a m p i c i l l i nm e d i u ma n dg r o w nt oa nO . D .
of 0.5 at 600 nm, then the culture was induced with
0.02% arabinose for 4 h at 37°C. The cells were har-
vested by centrifugation at 3000 rpm for 20 min and
lysed with Bugbuster Prote i nE x t r a c t i o nR e a g e n t
(Novagen, San Diego, USA) in the presence of 1 μg/ml
DNase, 1 μg/ml RNase and protease inhibitor cocktail
(Sigma) at 25°C for 20-30 min. The lysate was centri-
fuged and separated into supernatant (soluble fraction)
and pellet (insoluble fraction) and analyzed on SDS-
PAGE. The soluble fraction was purified by Ni-NTA
(Qiagen) affinity for the 6xHis tag of the expressed
peptide under native conditions to near homogeneity.
Proteins were also confirmed by Western blotting for
6xHis by Penta.His HRP (Qiagen). Protein concentra-
tion was measured using a Bio-Rad Protein Assay Kit
(Bio-Rad) with bovine serum albumin (BSA) as a stan-
dard, and by densitometry measurements of the pro-
t e i nb a n d so nS D S - P A G Eg e l su s i n gk n o w np r o t e i n
concentration standards such as Trx.
Non-fusion proteins were prepared by cloning the
candidates in pCOLDII vector (Takara). The plasmids
were transformed into Rosetta-gami (DE3) pLacI (Nova-
gen). For expression, colonies were grown in LB med-
ium containing 50 μg/ml ampicillin at 37°C for 16 h. A
small portion of the culture was added to fresh LB-
ampicillin medium and grown to an O.D. of 0.5 at
600 nm. The culture was incubated at 4°C for 30 min.
and induced with 0.1 mM IPTG for 15 h at 15°C. The
cells were harvested by centrifugation at 3000 rpm for
20 min and lysed with Bugbuster Protein Extraction
Reagent in the presence of 1 μg/ml DNase, 1 μg/ml
RNase and protease inhibitor cocktail at 25°C for 20-30
min. The lysate was centrifuged and separated into solu-
ble and insoluble fractions. The insoluble fraction was
purified to provide inclusion bodies, dissolved in buffer
containing 50 mM CAPS, pH 11.0, 0.3% N-lauroylsarco-
sine and 0.1% b-mercaptoethanol (Sigma), purified on a
Ni-NTA affinity column under denaturing conditions to
near homogeneity, analyzed on tricine-PAGE and con-
firmed by Western blotting for 6xHis. Lysozyme was
used as a concentration reference.
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of 1 mM oxidized glutathione and 10 mM reduced glu-
tathione (Sigma). The proteins were also refolded under
identical redox conditions in the presence of immobi-
lized protein disulfide isomerase (PDI; Takara) at a ratio
equimolar to the soluble protein. Protein concentration
was measured with a Bio-Rad Protein Assay Kit (Bio-
Rad) using bovine serum albumin (BSA) as a standard
and/or by densitometry of protein bands on tricine-
PAGE gels with known protein concentration standards
such as lysozyme.
Proteins refolded under both conditions were analyzed
by circular dichroism spectroscopy on a Jasco J-805
spectropolarimeter. Proteins were prepared in PBS at
0.3-0.5 mg/ml and measurements taken at 25°C from
195-260 nm.
Binding and inhibition assays
1. Binding assay for dissociation constant (Kd)
Binding affinity of the proteins was assayed as
described by Friguet et al. [25] with several modifica-
t i o n s .Ac o n s t a n ta m o u n to fp r o t e i n( 1 0 - 2 5n M )w a s
incubated with varying amounts of IL-6R (1 nM-1 μM)
in PBS-BSA (0.01% BSA) at 25°C for 1 h. Proper con-
trols were included. The mixture was applied to a con-
stant amount of IL-6R coated beads (200 nM) and
incubated further for 30 min. After several washings
with PBS-T (Tween-20, 0.1%), streptavidin horseradish
peroxidase (SA-HRP; Amersham Biosciences) at 1/2000
dilution or Penta.His-HRP (Qiagen) at 1/1000 dilution
was added and incubated for 30 min - 1 h. The superna-
tant was removed and the beads were washed 4-5 times
with PBS-T. TMB substrate (200 μl) was added for
color development and the reaction was stopped with
0.5 M H2SO4. Absorbance was monitored at 450 nm.
Data were plotted using GraphPad Prism 4 (GraphPad
Software Inc., San Diego, CA, USA).
2. Inhibition assay for IC50
Inhibition of the IL-6/IL-6R interaction by the pro-
teins was assayed by competitive inhibition experiments.
A fixed amount of biotinylated IL-6 (45 nM, i.e.,~ 3
times the Kd) and varying amounts of protein/peptide (1
nM - 2 μM) were incubated with a constant amount of
IL-6R coated beads (350 nM) in PBS-BSA at 25°C for 1
h. After several washings with PBS-T, SA-HRP at 1/
2000 dilution was added and incubated for 30 min. The
supernatant was removed and the beads were washed 4-
5 times with PBS-T. TMB substrate (200 μl) was added
for color development, the reaction was stopped with
0.5 M H2SO4 and absorbance was monitored at 450 nm.
Data were plotted using GraphPad Prism 4 (GraphPad
Software Inc.).
3. Specificity assay
1 0 0n Mo fp r o t e i n sw a si n c u b a t e dw i t h1μMo fv a r -
ious soluble proteins (IL-6R, AChBP or IgG) at RT for 1
h. The mixtures were further incubated with 300 nM of
IL-6R coated beads for 1 h. The subsequent procedures
were as described for the binding assay.
Design of minimized peptides
Short cyclic peptides were designed based on the struc-
ture and disulfide pattern of 3F proteins. The sequences
of the peptides are shown in Table-1. The highly con-
served disulfide bonds in 3F proteins are C1-C3, C2-C4,
C5-C6 and C7-C8 (numbered according to the position
of the cysteine residues going from the N to the C ter-
minus) [10]. Therefore, we designed cyclic peptides con-
taining the individual loops sequences between C1-C3
(24 residues) where C2 was changed to G, C2-C4 (25
residues) where C3 was changed to G and C5-C6 (13
and 10 residues), respectively. If a cysteine was in the
loop sequence selected from the library, it was replaced
by serine (13-L1). In the case of 14-L3, due to mutation
of the C5 residue, a disulfide bond was formed between
the cysteine residue in the loop and C6. All the peptides
were synthesized and purified by (Invitrogen, Tokyo,
Japan).
Cellular assay
Cell culture and reagents: The lymphoblast cell line DS-
1 was obtained from the American Type Culture Collec-
tion (CRL-11102; Manassas, USA), and were cultured in
RPMI 1640 complete culture medium (Gibco, New
York, USA) supplemented with 10% fetal bovine serum
(FBS; Gibco), 10 mM HEPES buffer (Gibco), 10 U/ml
human IL-6 (Sigma, USA), penicillin (16 mg/l) and
streptomycin (25 mg/l) at 37°C in a humidified incuba-
tor with 5% CO2 [58]. The cells were routinely passaged
every 2 or 3 days in 35 mm flask (Falcon, Akasaka,
Japan). Cells were continuously cultured until harvest
for analysis.
Analysis of cell proliferation: Logarithmic growing DS-
1 cells were dispersed with pipetting, centrifuged at
3000 rpm for 5 min, washed two times in phosphate
buffer saline, and were finally resuspended in standard
culture medium without IL-6. Prior to the assay, the
DS-1 cells (~2 × 10
4 cells/ml) were cultured for 24 h in
triplicate in 24 well, flat-bottomed microtiter plates (Fal-
con) in 1 ml of culture medium. The candidate peptides,
IL-6 and anti-human IL-6R antibody (R & D Systems,
Minneapolis, USA) were prepared in standard medium
at desired concentration. After 24 h pre-cultivation, cells
were treated with IL-6 (10 U/ml) and specific antibody
(0.03 - 2 μg/ml), protein or peptide (10
-10 -1 0
-5 M) for
48 h, and then the cells were counted under an inverted
microscope (Olympus, Hatagaya, Japan).
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Additional file 1: Construction of the three-finger library. (A) Primary
structure of the three-finger protein, MicTx3, used in this study. The four
disulfide bonds formed between C1-C3, C2-C4, C5-C6 and C7-C8 are
conserved among the three-finger proteins across a wide variety of
species. The loops are shown in color and were randomized to generate
the libraries. (B) Genetic construct adopted for cDNA display. SP6
contains the sp6 promoter, capping site and Xenopus globin untranslated
sequence (UTR). ATG is the translation initiation codon. The 3F gene with
the three randomized loops provides the basis of the library. G3S is
spacer, 6XHis facilitates affinity purification by Ni-NTA, and Y-tag
facilitates ligation of mRNA to the puromycin linker which contains the
complementary Y-tag sequence. (C) Construction of library by overlap
PCR. (i) The library was constructed by joining the fragments listed in
supplementary Table-1 using overlap PCR in various steps. The portions
marked in orange denote the randomized residues. (ii) Analysis of the
PCR products by electrophoresis. The bands denote the respective
fragments. (D) Direct sequencing of the PCR products of the library. The
portions shown by arrows represent loops that were randomized. The
peaks are smaller than normal due to the presence of a mixture of
residues.
Additional file 2: List of oligonucleotides used for library
preparation and amplification. Oligonucleotides that were used in the
preparation of 3F library and the primers required for amplification of the
selected library are listed.
Additional file 3: Design of shorter peptides containing disulfide
bonds from the parent 3F. (A) Scheme for designing peptides. 3F is a
leaf-like flat molecule with the three fingers extending from the globular
head. The three fingers were designed to split into three individual
fingers. (B) Design of the peptides. Primary sequence of the three-finger
protein. The four disulfide bonds are formed between C1-C3, C2-C4, C5-
C6 and C7-C8. The loops are located between the disulfide bonds. (ii)
Short peptides from the 3F sequence. The sequences of each of the
peptides correspond to one of the loops. In Loop-1 (L-1), C2 was
replaced by G, and in L-2, C3 was changed to G to restore the disulfide
bonds as in the parent 3F. In the case of R10-14, C5 was found to be
mutated to Y, however, a cysteine residue was selected in the
randomized loop. Therefore, a disulfide bond was formed between this
cysteine and C6.
Acknowledgements
The authors are grateful to Mr. Toshikatsu Kobayashi for his kind advices and
generous cooperation. We thank Drs. T. Toda and Y. Tamura for cooperation;
and J. Yamaguchi, S. Ohtaki and S. Honda for support. This work was
supported by the Strategic Research Center (Super COE) Development
Program of Special Coordination Funds for Promoting Science and
Technology, Ministry of Education, Culture, Sports, Science and Technology
(MEXT) and Innovation Center for Start-Ups, National Institute of Advanced
Industrial Science and Technology, Japan and in part by New Energy and
Industrial Technology Development Organization (NEDO), Japan.
Author details
1Applied Gene Technology, Institute for Biological Resources and Functions,
National Institute of Advanced Industrial Science and Technology, Central 6,
1-1-1, Higashi, Tsukuba, Ibaraki 305-8566, Japan.
2Innovation Center for Start-
ups, National Institute of Advanced Industrial Science and Technology, 2-2-2,
Marunouchi, Chiyoda-ku, Tokyo, 100-0005, Japan.
3Molecular
Neurophysiology, Neuroscience Research Institute, National Institute of
Advanced Industrial Science and Technology, Central 6, 1-1-1 Higashi,
Tsukuba, Ibaraki 305-8566, Japan.
4Department of Regulation Biology, Faculty
of Science, Saitama University, 255 Shimo-okubo, Sakura-ku, Saitama, 338-
8570, Japan.
5Janusys Corporation, #508, Saitama Industrial Technology
Center, Skip City, 3-12-18 Kami-Aoki, Kawaguchi, Saitama, 333-0844, Japan.
6United Graduate School of Drug Discovery and Medical Information
Sciences, Gifu University, 1-1 Yanagido, Gifu, Gifu 501-1193, Japan.
7Biomedical Research Institute, National Institute of Advanced Industrial
Science and Technology, Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566,
Japan.
Authors’ contributions
MN designed and performed most of the experiments, analyzed the data
and wrote the manuscript. SK prepared the proteins, multiple alignment and
protein structures. CT and TS performed cellular assays and wrote a part of
the manuscript. MM and NN analyzed the data. TK conceived the study,
analyzed the data and wrote the manuscript. All authors approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 14 December 2010 Accepted: 7 January 2011
Published: 7 January 2011
References
1. Pluckthun A, Schaffitzel C, Hanes J, Jermutus L: In vitro selection and
evolution of proteins. Adv Protein Chem 2000, 55:367-403.
2. Smith GP: Filamentous fusion phage: novel expression vectors that
display cloned antigens on the virion surface. Science 1985,
228:1315-1317.
3. Lipovsek D, Pluckthun A: In-vitro protein evolution by ribosome display
and mRNA display. J Immunol Methods 2004, 290:51-67.
4. Nemoto N, Miyamoto-Sato E, Husimi Y, Yanagawa H: In vitro virus:
bonding of mRNA bearing puromycin at the 3’-terminal end to the C-
terminal end of its encoded protein on the ribosome in vitro. FEBS Lett
1997, 414:405-408.
5. Roberts RW, Szostak JW: RNA-peptide fusions for the in vitro selection of
peptides and proteins. Proc Natl Acad Sci USA 1997, 94:12297-12302.
6. Yamaguchi J, Naimuddin M, Biyani M, Sasaki T, Machida M, Kubo T,
Funatsu T, Husimi Y, Nemoto N: cDNA display: a novel screening method
for functional disulfide-rich peptides by solid-phase synthesis and
stabilization of mRNA-protein fusions. Nucleic Acids Res 2009, 37(16):e108.
7. Binz HK, Pluckthun A: Engineered proteins as specific binding reagents.
Curr Opin Biotechnol 2005, 16:459-469.
8. Nygren PA, Skerra A: Binding proteins from alternative scaffolds. J
Immunol Methods 2004, 290:3-28.
9. Binz HK, Amstutz P, Pluckthun A: Engineering novel binding proteins
from nonimmunoglobulin domains. Nat Biotechnol 2005,
23:1257-1268.
10. Endo T, Tamiya N: Current view on the structure-function relationship of
postsynaptic neurotoxins from snake venoms. Pharmacol Ther 1987, 34:403-451.
11. Tsetlin V: Snake venom α-neurotoxin and other ‘three-finger’ proteins.
Eur J Biochem 1999, 264:281-286.
12. Miwa JM, Ibanez-Tallon I, Crabtree GW, Sánchez R, Sali A, Role LW, Heintz N:
Lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine
receptors in the mammalian CNS. Neuron 1999, 23:105-114.
13. Tsuji H, Okamoto K, Matsuzaka Y, Iizuka H, Tamiya G, Inoko H: SLURP-2, a
novel member of the human Ly-6 superfamily that is up-regulated in
psoriasis vulgaris. Genomics 2003, 81:26-33.
14. Fry BG, Wüster W, Kini RM, Brusic V, Khan A, Venkataraman D, Rooney AP:
Molecular evolution and phylogeny of elapid snake venom three-finger
toxins. J Mol Evol 2003, 57:110-129.
15. Teixeira-Clerc F, Menez A, Kessler P: How do short neurotoxins bind to a
muscular-type nicotinic acetylcholine receptor? J Biol Chem 2002,
277:25741-25747.
16. Bourne Y, Talley TT, Hansen SB, Taylor P, Marchot P: Crystal structure of a
Cbtx-AChBP complex reveals essential interactions between snake
alpha-neurotoxins and nicotinic receptors. EMBO J 2005, 24:1512-1522.
17. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of
interleukin 6. Immunol Today 1990, 11:443-449.
18. Hirano T, Kishimoto T: Interleukin 6 and autoimmune diseases. In
Molecular Autoimmunity. Edited by: Talal N. Academic Press; 1991:177-194.
19. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G,
Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its
regulation. Biochem J 2003, 374:1-20.
20. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M,
Bob P, Lerer B, Maj M: The inflammatory & neurodegenerative (I&ND)
Naimuddin et al. Molecular Brain 2011, 4:2
http://www.molecularbrain.com/content/4/1/2
Page 15 of 16hypothesis of depression: leads for future research and new drug
developments in depression. Metab Brain Dis 2009, 24:27-53.
21. Rasmussen P, Vedel JC, Olesen J, Adser H, Pedersen MV, Hart E, Secher NH,
Pilegaard H: humans IL-6 is released from the brain during and after
exercise and paralleled by enhanced IL-6 mRNA expression in the
hippocampus of mice. Acta Physiol (Oxf) 2010.
22. Antil S, Servent D, Menez A: Variability among the sites by which
curaremimetic toxins bind to torpedo acetylcholine receptor, as
revealed by identification of the functional residues of alpha-cobratoxin.
J Biol Chem 1999, 274:34851-34858.
23. Ferrari DM, Soling HD: The protein disulfide-isomerase family: unravelling
a string of folds. Biochem J 1999, 339:1-10.
24. Li J, Zhang H, Liu J, Xu K: Novel genes encoding six kinds of three-finger
toxins in Ophiophagus hannah (king cobra) and function
characterization of two recombinant long-chain neurotoxins. Biochem J
2006, 398:233-42.
25. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME: Measurements
of the true affinity constant in solution of antigen-antibody complexes
by enzyme-linked immunosorbent assay. J Immunol Methods 1985,
77:305-319.
26. Hoogenboom HR: Selecting and screening recombinant antibody
libraries. Nat Biotechnol 2005, 23:1105-1116.
27. Braisted AC, Wells JA: Minimizing a binding domain from protein A. Proc
Natl Acad Sci USA 1996, 93:5688-5692.
28. Xu L, Aha P, Gu K, Kuimelis RG, Kurz M, Lam T, Lim AC, Liu H, Lohse PA,
Sun L, Weng S, Wagner RW, Lipovsek D: Directed evolution of high-
affinity antibody mimics using mRNA display. Chem Biol 2002, 9:933-942.
29. Cho GS, Szostak JW: Directed evolution of ATP binding proteins from a
zinc finger domain by using mRNA display. Chem Biol 2006, 13:139-147.
30. Beste G, Schmidt FS, Stibora T, Skerra A: Small antibody-like proteins with
prescribed ligand specificities derived from the lipocalin fold. Proc Natl
Acad Sci USA 1999, 96:1898-1903.
31. Binz HK, Stumpp MT, Forrer P, Amstutz P, Plückthun A: Designing repeat
proteins: Well-expressed, soluble and stable proteins from combinatorial
libraries of consensus ankyrin repeat proteins. J Mol Biol 2003,
332:489-503.
32. Xie MH, Yuan J, Adams C, Gurney A: Direct demonstration of MuSK
involvement in acetylcholine receptor clustering through identification
of agonist scFv. Nat Biotechnol 1997, 15:768-771.
33. Rowley MJ, O’Connor K, Wijeyewickrema L: Phage display for epitope
determination: a paradigm for identifying receptor-ligand interactions.
Biotechnol Annu Rev 2004, 10:151-188.
34. Frederickson S, Renshaw MW, Lin B, Smith LM, Calveley P, Springhorn JP,
Johnson K, Wang Y, Su X, Shen Y, Bowdish KS: A rationally designed
agonist antibody fragment that functionally mimics thrombopoietin.
Proc Natl Acad Sci USA 2006, 103:14307-14312.
35. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC,
Davis AM, Tansik RL, Mattheakis LC, Boytos CM, Schatz PJ, Baccanari DP,
Wrighton NC, Barrett RW, Dower WJ: Peptide agonist of the
thrombopoietin receptor as potent as the natural cytokine. Science 1997,
276:1696-1699.
36. McConnell SJ, Dinh T, Le MH, Brown SJ, Becherer K, Blumeyer K, Kautzer C,
Axelrod F, Spinella DG: Isolation of erythropoietin receptor agonist
peptides using evolved phage libraries. Biol Chem 1998, 379:1279-1286.
37. Baneyx F, Mujacic M: Recombinant protein folding and misfolding in
Escherichia coli. Nat Biotechnol 2004, 22:1399-1408.
38. Levandoski MM, Caffery PM, Rogowski RS, Lin Y, Shi QL, Hawrot E:
Recombinant expression of alpha-bungarotoxin in Pichia pastoris
facilitates identification of mutant toxins engineered to recognize
neuronal nicotinic acetylcholine receptors. J Neurochem 2000,
74:1279-1289.
39. Love RA, Stroud RM: The crystal structure of alpha-bungarotoxin at 2.5 Å
resolution: relation to solution structure and binding to acetylcholine
receptor. Protein Eng 1986, 1:37-46.
40. Tsernoglou D, Petsko GA: The crystal structure of a post-synaptic
neurotoxin from sea snake at 2.2 Å resolution. FEBS Lett 1976, 68:1-4.
41. Silverman J, Liu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A,
Li P, Le H, Whitehorn E, Moore KW, Swimmer C, Perlroth V, Vogt M,
Kolkman J, Stemmer WP: Multivalent avimer proteins evolved by exon
shuffling of a family of human receptor domains. Nat Biotechnol 2005,
23:1556-1561.
42. Qiu XQ, Wang H, Cai B, Wang LL, Yue ST: Small antibody mimetics
comprising two complementarity-determining regions and a framework
region for tumor targeting. Nat Biotechnol 2007, 25:921-929.
43. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M,
Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA,
Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T,
Galle PR, Rose-John S, Neurath MF: Blockade of interleukin 6 trans
signaling suppresses T-cell resistance against apoptosis in chronic
intestinal inflammation: evidence in crohn disease and experimental
colitis in vivo. Nat Med 2000, 6:583-588.
44. Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL,
Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset
obesity. Nat Med 2002, 8:75-79.
45. Chida D, Osaka T, Hashimoto O, Iwakura Y: Combined interleukin-6 and
interleukin-1 deficiency causes obesity in young mice. Diabetes 2006,
55:971-977.
46. Fee D, Grzybicki D, Dobbs M, Ihyer S, Clotfelter J, Macvilay S, Hart MN,
Sandor M, Fabry Z: Interleukin 6 promotes vasculogenesis of murine
brain microvessel endothelial cells. Cytokine 2000, 12:655-665.
47. Woiciechowsky C, Schöning B, Cobanov J, Lanksch WR, Volk HD, Döcke WD:
Early IL-6 plasma concentrations correlate with severity of brain injury
and pneumonia in brain-injured patients. J Trauma 2002, 52:339-45.
48. Quintana A, Molinero A, Borup R, Nielsen FC, Campbell IL, Penkowa M,
Hidalgo J: Effect of astrocyte-targeted production of IL-6 on traumatic
brain injury and its impact on the cortical transcriptome. Dev Neurobiol
2008, 68:195-208.
49. Nishimoto N, Kishimoto T, Yoshizaki K: Anti-interleukin 6 receptor
antibody treatment in rheumatic disease. Ann Rheum Dis 2000, 59:21-27.
50. Su JL, Lai KP, Chen CA, Yang CY, Chen PS, Chang CC, Chou CH, Hu CL,
Kuo ML, Hsieh CY, Wei LH: A novel peptide specifically binding to
interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth.
Cancer Res 2005, 65:4827-4835.
51. Feng J, Li Y, Shen B: The design of antagonist peptide of hIL-6 based on
the binding epitope of hIL-6 by computer-aided molecular modeling.
Peptides 2004, 25:1123-1131.
52. Martin F, Toniatti C, Salvati AL, Venturini S, Ciliberto G, Cortese R,
Sollazzo M: The affinity-selection of a minibody polypeptide inhibitor of
human interleukin-6. EMBO J 1994, 13:5303-5309.
53. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM,
Pecorari F, Ward CW, Joos TO, Plückthun A: A designed ankyrin repeat
protein evolved to picomolar affinity to Her2. J Mol Biol 2007,
369:1015-1028.
54. Boder ET, Midelfort KS, Wittrup KD: Directed evolution of antibody
fragments with monovalent femtomolar antigen-binding affinity. Proc
Natl Acad Sci USA 2000, 97:10701-10705.
55. Wrighton NC, Balasubramanian P, Barbone FP, Kashyap AK, Farrell FX,
Jolliffe LK, Barrett RW, Dower WJ: Increased potency of an erythropoietin
peptide mimetic through covalent dimerization. Nat Biotechnol 1997,
15:1261-1265.
56. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Kroon D, Freedy J,
Zivin RA, Mulcahy LS, Jolliffe LK: Amino-terminal dimerization of an
erythropoietin mimetic peptide results in increased erythropoietic
activity. Chem Biol 1997, 4:939-950.
57. Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Pluckthun A:
PEGylation and multimerization of the anti-p185HER-2 single chain Fv
fragment 4D5: effects on tumor targeting. J Biol Chem 2006,
281:35186-35201.
58. Bock GH, Long CA, Riley ML, White JD, Kurman CC, Fleisher TA, Tsokos M,
Brown M, Serbousek D, Schwietermann WD, Nelson DL: Characterization of
a new IL-6 dependent human B-lymphoma cell line in long term
culture. Cytokine 1993, 5:480-489.
doi:10.1186/1756-6606-4-2
Cite this article as: Naimuddin et al.: Directed evolution of a three-finger
neurotoxin by using cDNA display yields antagonists as well as agonists
of interleukin-6 receptor signaling. Molecular Brain 2011 4:2.
Naimuddin et al. Molecular Brain 2011, 4:2
http://www.molecularbrain.com/content/4/1/2
Page 16 of 16